Abstract: Urinary tract infections, genital tract infections and sexually transmitted infections are the most prevalent infectious diseases, and the establishment of locally optimized guidelines is critical to provide appropriate treatment. The Urological Association of Asia has planned to develop the Asian guidelines for all urological fields, and the present urinary tract infections, genital tract infections and sexually transmitted infections guideline was the second project of the Urological Association of Asia guideline development, which was carried out by the Asian Association of Urinary Tract Infection and Sexually Transmitted Infection. The members have meticulously reviewed relevant references, retrieved via the PubMed and MEDLINE databases, published between 2009 through 2015. The information identified through the literature review of other resources was supplemented by the author. Levels of evidence and grades of recommendation for each management were made according to the relevant strategy. If the judgment was made on the basis of insufficient or inadequate evidence, the grade of recommendation was determined on the basis of committee discussions and resultant consensus statements. Here, we present a short English version of the original guideline, and overview its key clinical issues.
Introduction
UTIs, GTIs and STIs are the most prevalent infectious diseases with a substantial financial burden on the community. Many clinicians are confronted with these diseases, and the establishment of locally optimized guideline is critical to provide appropriate treatment. Thus, it is unquestionably necessary to have integrated Asian guidelines. We also need to know the status of diseases, antimicrobial resistance patterns and management strategies in Asia. This guideline provides recommendations based on current evidence for best practice in the management of adults and children with UTIs, GTIs and STIs. In this paper of summarized Asian guidelines on UTIs, it includes adult women (including pregnant women) and men of all ages, patients with indwelling catheters and patients with comorbidities, such as neurogenic bladder, urinary tract obstructions and DM. It also includes children and patients with urogenital tract tuberculosis. This guideline will be of interest to urologists, healthcare professionals in primary and secondary care, officers in charge of residential and care homes, antibiotic policy makers, clinical effectiveness leads, primary clinicians, and patients. Additional information and discussion of this guideline are available on the AAUS website (http://www.aaus.info).
relevant references, retrieved via the PubMed and MED-LINE databases, published from 2009 to 2015. Furthermore, the International Consultation on Urological Diseases book of Urogenital Infections (2010) 1 covering the topic UTIs and STIs has been looked through for systematic literature searches carried out until 2008 or 2009. The information identified through the literature review of other resources was supplemented by the author. Levels of evidence and grades of recommendation (Table S2) for each management were established according to the following strategy. References used in the guidelines have been assessed according to the level of scientific evidence involved, and guideline recommendations have also been evaluated according to the Agency for Health Care Policy and Research. 2 When the evidence was insufficient or of an inappropriate level to make the judgment, the grade of recommendation was determined according to committee discussions and resultant consensus statements (Table S3 ).
Urinary tract infections
Acute uncomplicated cystitis AUC frequently occurs in young sexually active, as well as postmenopausal, women without relevant structural or functional abnormalities within the urinary tract. 3 Escherichia coli is the predominant pathogen most frequently isolated (approximately 75%) during episodes of AUC, followed by Staphylococcus saprophyticus. [4] [5] [6] Occasionally, other pathogens, such as Enterococcus faecalis, Klebsiella pneumoniae and Proteus mirabilis, are involved.
7-9 Diagnosis of AUC can be made with a high probability based on a history of urinary irritative symptoms, absence of fever and physical examination findings in women who have no risk factors for complication with a UTI. 10 A urine dipstick test is useful for diagnosis of AUC. 11, 12 Microscopy of urine sediment is recommended, not only to secure the diagnostic accuracy, but also to distinguish between coccus-and coli-forms (LE: 2a, GR: B). A urine culture is recommended before treatment for patients with a high risk for drug resistance in order to avoid an inappropriate choice of antimicrobials (LE: 4, GR: B). 10 A colony count of ≥10 3 cfu/mL of uropathogens is required for microbiological diagnosis in patients presenting with symptoms of AUC (LE: 2b, GR: B).
13 Table 1 shows the recommended antimicrobial agents and duration of treatment for AUC. The standard antimicrobial drugs for treatment of AUC are fosfomycin trometamol, nitrofurantoin macrocrystals (LE: 1a, GR: A), TMP/SMX (LE: 2a, GR: B) and b-lactams, including cephalexin, cefaclor and amoxicillin/clavulanate (LE: 1a, GR: A). If Gram-positive cocci are present, amoxicillin/clavulanate could be recommended, because the drug is active against enterococci and staphylococci (LE: 1a, GR: A). Fluoroquinolones should be considered only as an alternative choice in young sexually active women with S. saprophyticus (LE: 3, GR: B), but not as the first choice for treatment of AUC (LE: 1a, GR: A). Third-generation oral cephalosporins, including cefdinir, cefcapene-pivoxil and cefpodoxime-proxetil, are alternative choices when other recommended agents cannot be used, but should not be prescribed if cocci are present (LE: 1a, GR: A). Amoxicillin or ampicillin should not be prescribed for empirical treatment because of the high prevalence of antimicrobial resistance to these agents worldwide (LE: 2a, GR: B). It should be noted that in some Asian countries, the resistance of E. coli against TMP/SMX, b-lactams and fluoroquinolones might be >20%, a recommended threshold for empiric therapy.
14-17 Pregnant women with AUC or asymptomatic bacteriuria should be treated with the standard regimen of antimicrobials (LE: 1b, GR: A). 18 Fluoroquinolones, tetracycline and TMP/SMX should be avoided because of their associated toxicity in newborns (LE: 1b, GR: A). 19 
Acute uncomplicated pyelonephritis
Pyelonephritis is the inflammation of the renal parenchyma and renal pelvis by ascending infection in the urinary tract. Renal tissue destruction spreads to the parenchyma and it is easy to induce sepsis or bloodstream infection. It is classified as acute uncomplicated UTI and complicated UTI with the underlying disease. The spectrum of etiological bacteria is similar in uncomplicated upper and lower UTIs from the infectious mechanism, with E. coli the causative pathogen in approximately 80% of cases. 8 The renal excretion type antibiotics, such as b-lactams and quinolones, are recommended (LE: 1a, GR: A). [20] [21] [22] We must determine the effect of empirical therapy to guide the 3 days after the start of treatment. Then, in accordance with bacterial culture results, it is necessary to switch to definitive therapy (LE: 2a, GR: A). We recommend switching to oral medications from parenteral antimicrobial agents by approximately 24 h after symptom remission, such as antipyretics. The total duration of administration is for 14 days (LE: 1a, GR: A). An oral agent is selected for the first-line chemotherapy to the outpatients, who are mild or moderate cases of acute uncomplicated pyelonephritis. However, the combination of a single injection of the drug during the first visit is also recommended (LE: 1a, GR: A). When we find special conditions, such as hydronephrosis, abscess formation and gas production, we must diagnose accurately and quickly, and carry out a urological procedure to hold the renal function (LE: 2a, GR: A). We recommend combination therapy for more severe cases in pyelonephritis patients with urosepsis, severe sepsis and septic shock (LE: 2a, GR: A). The algorithm of diagnosis and treatment for acute pyelonephritis is presented in Figure 1 .
Complicated UTIs with neurogenic bladder
UTI in patients with neurogenic bladder causes significant morbidity and mortality. 23 causes atypical symptomatology, including cloudy urine, foul smelling urine, fever, malaise and lethargy, new or increased urine leakage, increased spasticity, autonomic dysreflexia, loin pain, suprapubic pain, and dysuria. Urine tests are pivotal in confirming or excluding UTI, and in guiding appropriate antibiotic treatment. Quantitative criteria of significant bacteriuria, as defined by urine culture, are clean-void urine with ≥10 4 cfu/mL, urine from intermittent catheterization with ≥10 2 cfu/mL and any detectable concentration in suprapubic aspirate or urine specimen from an indwelling catheter. 24, 25 Symptomatic UTI warrants antibiotic treatment. Optimal duration of therapy has not been established. 26 It ranges generally from five to a maximum of 14 days depending on severity. Seven days of therapy is most commonly used (LE: 3, GR: B). [25] [26] [27] There is no definite superiority of one agent or class of antimicrobials, and regional differences in antibiotic resistance patterns need to be taken into consideration (LE: 3, GR: B). 28 Lack of pyuria reasonably predicts the absence of UTI in neurogenic bladder (LE: 2b, GR: B). 26, 29 Asymptomatic bacteriuria should not be treated, 26 even in cases of intermittent catheterization, 25 because it has not been shown to be beneficial and it increases the risk of developing antimicrobial resistance (LE: 1a, GR: A). 30 Also, antibiotic prophylaxis is generally not recommended because its benefit is unproven, and it is associated with development of antimicrobial resistance (LE: 1a, GR: A). 26, 30 Adequate bladder drainage is essential in reducing the occurrence of urinary tract infections (LE: 2b, GR: B). 31, 32 Recurrent UTI in neurogenic bladder might necessitate the treatment of neurogenic detrusor overactivity, and the restoration of low bladder pressure during bladder storage and voiding by drugs or surgery. 33 
Complicated UTIs with BPH
The kind of causative bacteria is the same in general UTI. The purpose of this chapter is to distinguish surgically correctable cases from those that require medical therapy including antibiotics. BPH-related UTI is characterized by difficulty in correction of pyuria with antibiotics. There is no clear evidence showing that the occurrence of UTI in the aging male population is associated with either postvoid residual or bladder outlet obstruction, therefore antibiotic prophylaxis is not indicated for such patients (LE: 2b, GR: B). 34 In men with lower urinary tract symptoms as a result of to BPH, the risk of UTI is low, therefore antibiotic prophylaxis is not indicated (LE: 1b, GR: A). In patients with early recurrent or persistent UTI, imaging and urological investigations should be carried out to identify underlying abnormalities that might be surgically correctable (LE: 1b, GR: A). Medical therapy for BPH; that is, alpha-blocker and/or 5a-reductase inhibitor, cannot reduce the incidence of UTI (GR: A). 35 Recurrent or persistent UTI in men with bladder outlet obstruction and BPH is an indication for prostatectomy (GR: A). [36] [37] [38] The presence of infection in patients with BPH should prompt appropriate evaluation and therapy before treatment of BPH (GR: A). 39 Screening for and treatment of asymptomatic bacteriuria before transurethral resection of the prostate is recommended (GR: A). [40] [41] [42] [43] An assessment for the presence of bacteriuria should be obtained, so results will be available to direct antimicrobial therapy before the procedure (GR: A). Antimicrobial therapy should be initiated shortly before the procedure (GR: A). 40, 44 Antimicrobial therapy should not be continued beyond the procedure, unless an indwelling catheter remains in place (GR: B). 40, 45 Complicated UTIs with urolithiasis Urolithiasis might be a cause as well as a result of UTI. Stone obstruction leads to urinary stasis, which enables bacteria to adhere to the urothelium and multiply, thus causing UTI. The kind of causative bacteria is the same in general UTI. Patients with BPH-related UTI are characterized as a kind of natural process which aggravates with age. In contrast, UTI with urolithiasis could be found in both male and female patients, without aging-related characteristics. Primary UTI caused by urea-splitting organisms can lead to struvite stone formation, causing obstruction, stasis and further infection. This is the clinical consequence of the "vicious cycle:" stones ? obstruction ? stasis ? infection ? stones. Obstructive pyelonephritis is also one of the life-threatening complications of UTI, and prompt diagnosis and treatment, including medical as well as surgical interventions, are required to rescue the patients. Complicated UTIs with urolithiasis are discussed in the chapter. Although it is not sufficient to exclude the presence of UTI, midstream urine culture should be obtained before any treatment is planned (GR: A). 46, 47 In the case of a UTI with systemic symptoms (fever, but also chills and low temperature), blood culture must be carried out (GR: A). Image studies including ultrasound and computed tomography are highly recommended for diagnosis and evaluation of UTI associated with urolithiasis (GR: A). [48] [49] [50] For sepsis with obstructing stones, the collecting system should be urgently decompressed, using percutaneous drainage or ureteral stenting (GR: A). 51 Specific indication of the decompressive method is not yet established. Definitive treatment of the stone should be delayed until sepsis is resolved (GR: A). Urine should be collected for an antibiogram test after decompression (GR: A). Antibiotics should be started immediately thereafter (+intensive care if necessary; GR: A). The antibiotic regimen should be re-evaluated after antibiogram findings (GR: A). Recommendations for therapeutic measures of infection stones are as follows: surgical removal of the stone material as complete as possible with diverse available technique (GR: A); short-term antibiotic course (GR: B); long-term antibiotic course (GR: B); urinary acidification: ammonium chloride 1 g, two or three times daily (GR: B); urinary acidification: methionine 200-500 mg, one to three times daily (GR: B); and urease inhibition (GR: A). The antimicrobial treatment options of empirical therapy for UTI with urolithiasis are listed in Table 2 . 52 
Complicated UTIs with DM
DM has a number of long-term effects on the genitourinary system. Patients with DM are at increased risk for UTI 53 because of the multiple effects of this disease on the urinary tract, including immunological impairment 54 or inadequate bladder emptying. 55 A higher glucose concentration in the urine might act as a culture medium for pathogenic microorganisms. The prevalence of UTI has an association with glycemic control in DM patients. 56 Bacteriuria is more common in women with DM than in non-diabetic women because of a combination of host and local risk factors. Upper urinary tract infection complications are also more common in this group. The treatment of UTI in patients with DM does not differ from the treatment in those without the disease in terms of antimicrobial choice or duration of therapy (LE: 4, GR: C). 57 With asymptomatic bacteriuria, antibiotic treatment is not recommended in non-pregnant women of any age (LE: 1b, GR: A). 58 DM is frequently associated with the more severe manifestations of UTI. Patients with DM are more likely to be hospitalized for the treatment of pyelonephritis, more likely to have a bacteremic infection and more frequently have bilateral renal infection compared with populations without DM. EPN is a severe, necrotizing infection of the renal parenchyma. EPN most often occurs in persons with DM, especially women. The clinical course of EPN can be severe and lifethreatening if the disease is not recognized and treated promptly. In EPN, computed tomography is the imaging procedure of choice to confirm the presence and extent of parenchymal gas (LE: 3b, GR: B). 59 In EPN, nephrectomy is limited to selected groups who are fit for surgery and fulfill one or more of the following criteria: possession of a nonfunctioning kidney or presentation of gross renal parenchymal destruction (LE: 4, GR: C). In emphysematous cystitis, systemic antimicrobials and relief of any complicating bladder outlet obstruction, if present, are adequate therapy (LE: 4, GR: C). In a patient with a UTI with a persistent fever after 3-4 days of antibiotics, consider papillary necrosis, renal abscess or EPN (LE: 4, GR: C).
Catheter-associated UTIs
CAUTI refers to UTIs associated with indwelling urinary catheters, which are defined as drainage tubes inserted into the urinary bladder through the urethra, left in place and connected to a collection system. 60 CAUTIs are the most common nosocomial infections. 61, 62 The definition of CAUTI remains controversial, with many guidelines agreeing that symptoms alone are not reliable for the diagnosis of CAUTI. The National Healthcare Safety Network definitions have been widely accepted. 63 Candida species are the most common uropathogens, followed by Enterococci, E. coli, Pseudomonas spp., Klebsiella spp. and Staphylococci. 64 Higher rates of CAUTIs and antibiotic-resistant organisms have been reported in parts of Asia. Hence, antimicrobial treatment choice should be guided by local antibiograms and culture results (LE: 4). CAASB should not be routinely treated with antibiotics (LE: 1b). Routine surveillance cultures are not warranted and should not be carried out (Fig. 2) . 65 Reducing the duration of urethral catheterization remains key to the prevention of CAUTIs (LE: 2b), for which various reminder systems have been shown to be effective (LE: 1a). Urinary catheter care bundles have also been shown to reduce CAUTI rates (LE: 2a; Table 3 ).
Urogenital TB
UGTB is a unique kind of UTI caused by a single causative pathogen. Recently, the prevalence of UGTB has not been so high, but in some Asian countries, it is still prevalent and we should be aware of this condition. In particular, BCG-induced bladder TB is clinically important to urologists.
According to World Health Organization reports, reviewed in March 2014, approximately one-third of the world's population has latent TB, which means people have been infected by Mycobacterium tuberculosis but are not (yet) ill with the disease and cannot transmit the disease. People infected with M. tuberculosis have a lifetime risk of falling ill with TB of 10%. In 2012, the largest number of new TB cases occurred in Asia, accounting for 60% of new cases globally. UGTB is the second to third most frequent form of TB, but a large proportion of patients are underdiagnosed (LE: 2). [66] [67] [68] Male genital TB is usually (>50%) associated with PTB and/or renal TB (actual or cured), but isolated forms are also possible. More often, the epididymis and prostate are involved (LE: 1). [69] [70] [71] The main route of infection is through hematogenous and lymphatic spread, but direct extension from infected urine and ejaculate spread is also possible (LE: 1).
All patients with genital TB should be screened for chest and upper urinary tract involvement and HIV infection (GR: A). At least three, but preferably five, serial microbiological studies with urine (including post-ejaculate and postmassage urine), ejaculate and prostate secretion including smears, cultures, including automated system (GR: A) and polymerase chain reaction (GR: B) should be carried out to 72 In difficult cases, a provocative subcutaneous tuberculin test is recommended (GR: B). 73 Radiological studies are not useful for diagnosis of UGTB in the early stages, before development of tissue destruction (LE: 2). For cavernous prostate TB, retrograde urethrography is crucial (GR: A). Fine-needle aspiration cytology is an accurate and rapid diagnostic tool for scrotal TB, but might be complicated by TB generalization (GR: C). 72 Diagnosis of iatrogenic (BCG-induced) bladder TB (complication of BCG therapy for bladder cancer) might be made by clinical features -significant dysuria and decrease of the bladder volume; confirmation is only by histology, not by bacteriology (GR: C). Short-term treatment for 6-9 months is suitable for uncomplicated cases in regions with low incidence of TB (GR: B). In complicated cases (relapse, immunosuppression, drug resistance) and in epidemic regions, anti-TB therapy should be longer, up to 12-14 months with four to five drugs (GR: B; Table 4 treated with at least five anti-TB drugs for at least 18 months (GR: B). BCG-induced bladder TB should be treated with two or three anti-TB drugs for 2-4 months, if the volume is normal; if microcystis develops, cystectomy and following enteroplastic reconstructions are indicated with the same anti-TB therapy (GR: B). Patients with UGTB should be followed up for control of eradication, or if symptoms persist or recur after completion of the therapy every 6 months for 1-3 years, depending on the form and stage of the disease.
To prevent a relapse, repeated short-course (for 2 months) therapy with isoniazid and rifampicin is recommended for patients with complicated UGTB; in multidrug-resistant UGTB, preventive therapy is prescribed according to the sensitivity of M. tuberculosis. Specific prophylaxis from UGTB is absent now.
UTIs in children
UTI is a common infection in children and infants around the world. Classification according to the sites of infection (lower tract vs upper tract), the number of episodes (first vs recurrent), the severity (simple vs severe) or the existence of complicating factors (uncomplicated vs complicated) is useful to identify whether children with UTI are at risk of renal damage or not (LE: 2, GR: B; Table 5 ). The presence of UTI should be considered on the basis of clinical presentation, the age of the child and the severity of the disease. However, clinical symptoms/signs are not sufficiently accurate to definitively diagnose UTI (LE: 1a, GR: A). Diagnosis of UTI requires both urinalysis that suggests infection and positive urine culture (LE: 3, GR: B). For children not yet toilet trained, a urine specimen for culture should be collected by urethral catheterization or suprapubic aspiration. For toilet-trained children, midstream clean catch urine is reliable (LE: 3, GR: A). Urine culture is considered positive if it shows growth of a single bacterium with the following colony counts: (i) any growth by suprapubic aspiration; (ii) >5 9 10 4 cfu/mL by urethral catheterization; or (iii) >10 5 cfu/mL by midstream clean catch (LE: 3, GR: B). 74, 75 An appropriate antibiotic should be given immediately after urine specimen for culture has been obtained (LE: 2, GR: A). Initiating therapy with oral or parenteral antibiotics is equally efficacious for children (>3 months) with uncomplicated UTI (LE: 2, GR: A). 76 The choice of empirical antibiotic agents is guided by the expected pathogen and the local resistance patterns (LE: 2, GR: A). For children with febrile UTI, the total course of antibiotic therapy should be 7-14 days (LE: 2, GR: B). 1a/D The use of antibiotic prophylaxis during short-term urinary catheterization of up to 14 days in adult patients was reviewed in several randomized controlled trials. Meta-analysis showed only limited evidence in reduction of rates of bacteriuria, pyuria and febrile morbidity in surgical patients postoperatively, and reduction of symptomatic UTIs with antibiotic prophylaxis at the time of catheter removal. Meat-analysis on the use of antibiotic prophylaxis in patients requiring long-term intermittent or indwelling urinary catheterization showed inconsistent and limited evidence of efficacy. The decision to use antibiotic prophylaxis must consider local microbial prevalence and antibiotic resistance patterns, as well as the risk-benefit ratio and cost considerations of the antibiotic. In Asia, it is unlikely that prophylaxis will be effective in view of high rates of antimicrobial resistance, and it might have the unintended consequence of selecting for even more resistant pathogens. The potential benefit of preventing recurrent UTI by antimicrobial prophylaxis should be weighed against the risk of antimicrobial resistance with future infections (LE: 2, GR: B). Antimicrobial prophylaxis to prevent recurrent UTI might be considered in infants and children with or without VUR after the first UTI (LE: 1b, GR: B; Table 6 ).
77
The goals of imaging studies are to localize the infection (lower or upper tract UTIs), to show anatomical or functional abnormalities, to detect significant VUR and to detect congenital or acquired renal scarring (LE: 2, GR: B). 74 For children with febrile UTI, RBUS should be routinely carried out as soon as possible (LE: 3, GR: C).
78-80 RBUS should be followed up 6 months later in children with acute pyelonephritis and/or VUR (LE: 3, GR: C). Acute DMSA scan can be carried out when severe acute pyelonephritis or congenital hypodysplasia is noted on RBUS, or when the diagnosis of UTI is in doubt by the clinical presentation (LE: 3, GR: C). [80] [81] [82] [83] Late DMSA scan (>6 months after the febrile UTI) can be carried out in children with severe acute pyelonephritis, high-grade VUR, recurrent febrile UTIs or abnormal renal parenchyma on the follow-up RBUS (LE: 3, GR: C; Fig. 3) . 84, 85 VCUG should not be carried out routinely for children after the first febrile UTI. VCUG is indicated when abnormalities are apparent on either RBUS or DMSA scan or both (LE: 2, GR: B). 74 VCUG is also suggested after a repeat febrile UTI (LE: 2, GR: B).
Early recognition and management of lower urinary tract dysfunction and bowel dysfunction are important in prevention of UTI recurrence (LE: 2, GR: A). [86] [87] [88] Bladder dysfunction increases the risk of UTI and can lead to a significant delay in the resolution of VUR (LE: 2, GR: B). Antibiotic prophylaxis to prevent recurrent febrile UTI is indicated in children with moderate-to high-grade (III-V) VUR (LE: 1b, GR: A). 89, 90 Surgical intervention should be used to treat VUR in the setting of recurrent febrile UTI, because it has been shown to decrease the incidence of recurrent pyelonephritis (LE: 2, GR: B). There are diverse surgical methods for VUR, such as Lich-Gregoir, Politano-Leadbetter, Glenn-Anderson, Cohen, laparoscopic repair (including robot assisted) and endoscopic repairs by injection of a bulking agent. The detailed context for surgical methods is hard to be determined due to different preference of individual surgeon.
Breast-feeding might protect infants from UTI (LE: 2), and is strongly recommended for prevention of UTI in infants (LE: 3, GR: A). 91 Cranberry and related products might prevent UTI in children (LE: 3), and can be considered in the prevention of UTI in children (GR: C). 92, 93 Probiotics might prevent UTI in children (LE: 3), and can be considered in the prevention of UTI in children (GR: C).
94,95

Conclusion
The summary of the UAA-AAUS guideline for UTIs was delineated. Management of UTI should be based on scientific evidence, and tailored to the local cultural and social environment. Therefore, this work would have great significance. Finally, this UAA-AAUS guideline is scheduled to be revised according to the concerns of experts based on the updated information.
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